Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM EV-to-OCF is -9.15 as of Aug. 01, 2026. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, NovelStem International ranks better than 79.34% on this metric.
The historical rank and industry rank for NovelStem International's EV-to-OCF or its related term are showing as below:
NSTM'
s EV-to-OCF Range Over the Past 10 Years
Min: -9.15 Med: 0 Max: -9.15
Current: -9.15
During the past 13 years, the highest EV-to-OCF of NovelStem International was -9.15. The lowest was -9.15. And the median was .
NSTM's EV-to-OCF is ranked better than 79.34% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.26
vs NSTM: -9.15
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovelStem International (OTCPK:NSTM) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovelStem International's PE Ratio (TTM) for today is calculated as:
NovelStem International's share price for today is $0.01146.
NovelStem International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NovelStem International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where NovelStem International's EV-to-OCF falls into.
NovelStem International's current Enterprise Value is $2.41 Mil.
NovelStem International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International (NSTM) has a EV-to-OCF of -9.15 as of Aug. 01, 2026. According to the industry distribution chart, NovelStem International ranks #44 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 20.7%.
Is NovelStem International's EV-to-OCF too high?
NovelStem International's current EV-to-OCF is -9.15. Based on the distribution chart, NovelStem International ranks #44 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does NovelStem International's EV-to-OCF compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #44 out of 213 companies for EV-to-OCF. This places NovelStem International in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 6.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.26, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current EV-to-OCF is -9.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current EV-to-OCF of -9.15. The current EV-to-OCF is -9.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For NovelStem International (NSTM), the current EV-to-OCF is -9.15 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
